Business
GB Sciences' Chief Science Officer, Dr. Andrea Small-Howard, Has Been Invited to Join the Medical Cannabis in Neuroscience Panel at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology
GB Sciences' Chief Science Officer, Dr. Andrea Small-Howard, Has Been Invited to Join the Medical Cannabis in Neuroscience Panel at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology.
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n\n\n\nGB Sciences' Chief Science Officer, Dr. Andrea Small-Howard, Has Been Invited to Join the Medical Cannabis in Neuroscience Panel at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nGB Sciences' Chief Science Officer, Dr. Andrea Small-Howard, Has Been Invited to Join the Medical Cannabis in Neuroscience Panel at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology\nCanada NewsWire\nLAS VEGAS, Dec. 26, 2017\n\n\n\nLAS VEGAS, Dec. 26, 2017 /CNW/ -- GB Sciences, Inc. (OTCQB: GBLX) will be represented on the Medical Cannabis in Neuroscience Panel at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology to take place at the Marines' Memorial Club, San Francisco, on the 7th of January 2018. The event is held the day before the J.P. Morgan meeting, which provides an ideal opportunity for established pharmaceutical industry giants like AbbVie, Boehringer Ingelheim, Pfizer, Sanofi, Novartis, Merck, Eli Lilly, Johnson & Johnson, and Takeda to share their latest innovations in neuroscience therapeutics with their colleagues and the investment community; refer to link at: http://www.sachsforum.com/nif-about.html.\n\n\n\nDr. Andrea Small-Howard, Chief Science Officer, will serve on the Medical Cannabis in Neuroscience Panel on behalf of GB Sciences to discuss the opportunities and challenges of neuroscience product development in the cannabis biotech industry. GB Sciences has previously announced the development of its proprietary cannabis-based therapy for Parkinson's disease, which will begin first-in-human testing in 2018.  \n\n\"GB Sciences is honored to join representatives from Tilray, Aurora Cannabis, and Emerald Therapeutics in a discussion of new cannabis-based therapeutic options for patients with neurodegenerative conditions. For example, GB Sciences has developed a novel Parkinson's formulation, which leverages molecular synergies among multiple plant-derived active ingredients to in...